BriaCell Therapeutics Corp.
Close on Oct 19, 2026
- Market cap
- $24.51M
- P/E (TTM)
- –
- Dividend yield
- –
About BriaCell Therapeutics
Pharmaceutical Preparations, SIC 2834
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing targeted immunotherapies designed to recognize and eliminate cancer cells by utilizing the human immune system. The company's lead product candidate is Bria-IMT, an immunotherapy currently investigated in combination with the checkpoint inhibitor retifanlimab. It also advances related research through its BriaPro programs. As an early-stage biopharmaceutical organization conducting preclinical research and clinical evaluations, BriaCell has not yet commercialized therapies for retail or commercial end customers.
The company maintains operational activities, office premises, and research facilities across Canada and the United States. Its corporate headquarters and principal executive offices are situated in West Vancouver, British Columbia, Canada. BriaCell conducts its ongoing biotechnology development programs without maintaining commercial distribution storefronts or marketing-stage operations.
Summary of the business section of BriaCell Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BriaCell Therapeutics Corp.
- Headquarters
- West Vancouver, A1
- Address
- 3rd Floor, Bellevue Centre, 235-15th Str V7T 2X1
- Phone
- (604) 921-1810
- Website
- briacell.com
- Employees
- 22, Jul 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- July 31
- Auditor
- MNP LLP, Mississauga, Canada
Stock & identifiers
- Ticker
- BCTX
- Other tickers
- BCTXL, BCTXZ
- Exchange
- Nasdaq
- IPO date
- Feb 25, 2021
- Shares outstanding
- 9M, Jun 9, 2026
- Public float
- $94.48M, Jan 31, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Oct 16, 2025; 1-for-10 reverse, Aug 25, 2025; 1-for-15 reverse, Mar 12, 2025; 1-for-300 reverse, Jan 2, 2020
- SEC CIK
- 1610820
- CUSIP
- 107930307
- ISIN
- US1079303079
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
BriaCell Therapeutics's leadership is listed in its proxy statement, last filed Feb 12, 2026.
Employees
Headcount reported in annual reports
“As of the date of this filing, we had twenty-two full-time employees, located in various US states including: NY, FL, PA, SC, NV and NJ.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 26, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| Jan 13, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 24, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 23, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 5, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 25, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 23, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 20, 2014 | Name change | Name changed from Ansell Capital Corp. to BriaCell Therapeutics Corp. |